All In Biotech

Drug Trial Radar · NCT05612581

A Platform Study to Evaluate Investigational Therapies in Chronic Hepatitis B Infection

A Platform Study Evaluating the Efficacy and Safety of Investigational Therapies in Participants With Chronic Hepatitis B Infection (PREVAIL)

Last checked: Nov 19, 2026Latest source record: Feb 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

33

Actual

Start

May 10, 2023

Primary completion

Oct 15, 2024

Study completion Aug 19, 2025

Sponsor

Lead sponsor
Vir Biotechnology, Inc.Industry
Sponsor type
Industry
First posted
Nov 10, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 66 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 1b/2 platform study framework to evaluate the safety and efficacy of investigational candidate(s) and their combinations as potential treatments for adults with chronic hepatitis B virus infection.

Conditions

  • Hepatitis B, Chronic

Interventions

  • VIR-3434Drug

    VIR-3434 given by subcutaneous injection

  • VIR-2218Drug

    VIR-2218 given by subcutaneous injection

  • TDFDrug

    TDF given orally

  • PEG-IFNαDrug

    PEG-IFNα given by subcutaneous injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. STRIVE and THRIVE: Proportion of Participants Achieving Suppression of HBV DNA (< LLOQ) With HBsAg Loss (< 0.05 IU/mL) at the End of TreatmentTime frame: Up to 48 weeks

Locations

15 sites in 6 countries. Site status is shown where the registry gives one.

  • Investigative Site

    Clichy, France

  • Investigative Site

    Nice, France

  • Investigative Site

    Rennes, France

  • Investigative Site

    Toulouse, France

  • Investigative Site

    Hong Kong, Hong Kong

  • Investigative Site

    Hong Kong, Sha Tin, Hong Kong

  • Investigative Site

    Chisinau, Moldova

  • Investigative Site

    Bucharest, Romania

  • Investigative Site

    Busan, South Korea

  • Investigative Site

    Seoul, South Korea

  • Investigative Site

    Yangsan, South Korea

  • Investigative Site

    Glasgow, United Kingdom

  • Investigative Site

    London, United Kingdom

  • Investigative Site

    London, United Kingdom

  • Investigative Site

    Manchester, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.